ME02296B - Postupak za liječenje kancera dll4 antagonistom i hemoterapijskim agensom - Google Patents
Postupak za liječenje kancera dll4 antagonistom i hemoterapijskim agensomInfo
- Publication number
- ME02296B ME02296B MEP-2015-185A MEP18515A ME02296B ME 02296 B ME02296 B ME 02296B ME P18515 A MEP18515 A ME P18515A ME 02296 B ME02296 B ME 02296B
- Authority
- ME
- Montenegro
- Prior art keywords
- antigen
- binding fragment
- cancer
- seq
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (14)
1.Izolovane antitijela čoveka ili fragment za vezivanje antigena koji se specifično vezuje na ljudskom delta-sličnom ligandu 4 (hDII4) za upotrebu u lečenju kancera ili smanjenje ili zaustavljanje rasta tumora kod subjekta primenom u kombinaciji sa hemoterapijskim agensom, pri čemu ljudsko antitelo ili njegov fragment za vezivanje antigena obuhvata promenljivi region teškog lanca (HCVR) koji obuhvata CDR1, CDR2 i CDR3 teškog lanca sekvenci ID BR SEK:22, 24 i 26, respektivno, i promenljivi region lakog lanca (LCVR) koji obuhvata CDR1, CDR2 i CDR3 sekvence lakog lanca ID BR SEK:30, 32 l 34, respektivno, hemoterapijski agens je hemoterapijski agens na bazi platine ili analoga pirimidina, i kancer ili tumor je čvrst malignitet.
2.Ljudsko antitijela ili fragment za vezivanje antigena za upotrebu prema patentnom zahtjevu 1, pri čemu antitelo ili fragment za vezivanje antigena obuhvata HCVR sekvence ID BR SEK: 20 ili ID BR SEK: 116,ili LCVR sekvenca ID BR SEK: 28 ili ID BR SEK:118.
3.Ljudsko antitijela ili fragment za vezivanje antigena za upotrebu prema patentnom zahtjevu 1, pri čemu antitelo ili fragment za vezivanje antigena obuhvata HCVR /LCVR kombinaciju ID BR SEK: 20 /28 ili 116/118.
4.Ljudsko antitijela ili fragment za vezivanje antigena za upotrebu prema bilo kom patentnom zahtjevu 1-3, pri čemu: a) hemoterapijski agens na bazi platine jeste cisplatin, karboplatin, iproplatin, ili oksaliplatin; ili njihova farmaceutski prihvatljiva so; b) analog pirimidina je gemcitabin, 5-FU, ili kapecitabin; ili njihova farmaceutski prihvatljiva so.
5.Ljudsko antitijela ili fragment za vezivanje antigena za upotrebu prema patentnom zahtjevu 4, pri čemu je hemoterapijski agens cisplatin ili 5-FU.
6.Upotreba ljudskog antitijela ili fragmenta za vezivanje antigena obuhvata promenljivi region teškog lanca (HCVR) koji obuhvata teški lanac CDR1, CDR2 i CDR3 sekvence SEQ ID N0:22, 24 i 26, respektivno, i promenljivi region lakog lanca (LCVR) koji obuhvata laki lanac CDR1, CDR2 i CDR3 sekvence ID BR SEK:30, 32 i 34, respektivno u proizvodnji leka za lečenje kancera ili smanjenje ili zaustavljanje rasta tumora kod subjekta kome se primenjuje u kombinaciji sa hemoterapijskim agensom, pri čemu je hemoterapijski agens je hemoterapijski agens na bazi platine ili analoga pirimidina, i kancer ili tumor je čvrsti malignitet.
7. Ljudsko antitijela ili fragment za vezivanje antigena za upotrebu prema jednom od patentnih zahtjeva 1 do 5 ili upotrebu prema patentnom zahtevu 6, pri čemu se kancer bira iz grupe koja obuhvata kancer jajnika, kancer materice, kancer dojke, kancer pluća, kancer jetre, kolorektalni kancer, kancer bešike, kancer bubrega, kancer prostate, kancer pankreasa, kancer želuca, kancer kostiju, kancer kože, i maligni sarkom mekog tkiva.
8.Ljudsko antitijela ili fragment za vezivanje antigena za upotrebu ili za upotrebu prema patentnom zahtjevu 7, pri čemu se kancer bira iz kancera pluća, kolorektalnog kancera ili kancera bešike.
9.Ljudsko antitijela ili fragment za vezivanje antigena za upotrebu prema jednom od patentnih zahtjeva 1 do 5 i 7 do 8, ili upotreba prema jednom od patentnih zahteva 6 do 8, pri čemu se antitelo ili fragment za vezivanje antigena i hemoterapijski agens primenjuju istovremeno ili u sledu.
10.Ljudsko antitijela ili fragment za vezivanje antigena za upotrebu prema jednom od patentnih zahtjeva 1 do 5 i 7 do 8, ili upotreba prema jednom od patentnih zahteva 6 do 8, pri čemu se pomenuto antitelo ili fragment za vezivanje antigena primenjuje na ljudskom subjektu u kombinaciji sa pomenutim hemoterapijskim agensom.
11.Farmaceutsko jedinjenje koje obuhvata antitijela ili njegov fragment za vezivanje antigena obuhvata promenljivi region teškog lanca (HCVR) koji obuhvata CDR1, CDR2 i CDR3 teškog lanca sekvenci ID BR SEK:22, 24 i 26, respektivno, i promenljivi region lakog lanca (LCVR) koji obuhvata CDR1, CDR2 i CDR3 lakog lanca sekvenci ID BR SEK:30, 32 i 34, respektivno, hemoterapijski agens izabran iz hemoterapijskog agensa na bazi platine ili analoga pirimidina, opciono pri čemu hemoterapijski agens jeste cisplatin ili 5-FU , i farmaceutski prihvatljiv nosač.
12.Komplet koji u sebi sadrži posudu u kojoj se nalazi antitijela ili njegov fragment za vezivanje antigena obuhvata promenljivi region teškog lanca (HCVR) koji obuhvata CDR1, CDR2 i CDR3 teškog lanca sekvenci ID BR SEK:22, 24 i 26, respektivno, i promenljivi region lakog lanca (LCVR) koji obuhvata CDR1, CDR2 i CDR3 lakog lanca sekvenci ID BR SEK:30, 32 i 34, respektivno, i jednu ili više dodatnih posuda koje u sebi sadrže najmanje jedan hemoterapijski agens izabran iz hemoterapijskog agensa na bazi platine ili analoga pirimidina, opciono pri čemu hemoterapijski agens jeste cisplatin ili 5-FU.
13. Antitijela ili fragment za vezivanje antigena za upotrebu u postupku liječenja za smanjenje količine hemoterapijskog agensa neophode da se postigne željeno dejstvo lečenja kod subjekta koji ima kancer ili tumor, koji obuhvata primenu pomenutog antitela ili fragmenta za vezivanje antigena subjektu u kombinaciji sa hemoterapijskim agensom; pri čemu antitijela ili fragment za vezivanje antigena obuhvata promjenljivi region teškog lanca (HCVR) koji obuhvata CDR1, CDR2 i CDR3 teškog lanca sekvenci ID BR SEK:22, 24 i 26, respektivno, i promenljivi region lakog lanca (LCVR) koji obuhvata CDR1, CDR2 i CDR3 lakog lanca sekvenci ID BR SEK:30, 32 i 34, respektivno, pri čemu je hemoterapijski agens hemoterapijski agens na bazi platine ili analoga pirimidina, opciono pri čemu hemoterapijski agens jeste cisplatin ili 5-FU; i pri čemu je količina hemoterapijskog agensa smanjena u poređenju sa količinom potrebnom za isti terapijski agens u odsustvu antitela ili fragmenta za vezivanje antigena.
14.Antitijela ili fragment za vezivanje antigena za upotrebu prema patentnom zahtjevu 13, pri čemu je količina hemoterapijskog agensa neophodna da se postigne željeno terapijsko dejstvo smanjena za najmanje 20%, ili 30% do 50%. /// / 7 " --·----·· - .. ·-- - - D V 0 l< A -,- _ , Vido Đako n ov1c Mob. te l : 067/9 0 1 .. 0 1 4 1 email : ad v.djakonovic@gm a d .com BAJO\IA br .9, 81250 CET INJ E
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22046509P | 2009-06-25 | 2009-06-25 | |
| US30188110P | 2010-02-05 | 2010-02-05 | |
| EP10728555.3A EP2445528B1 (en) | 2009-06-25 | 2010-06-25 | Method of treating cancer with dll4 antagonist and chemotherapeutic agent |
| PCT/US2010/039999 WO2010151770A1 (en) | 2009-06-25 | 2010-06-25 | Method of treating cancer with dll4 antagonist and chemotherapeutic agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02296B true ME02296B (me) | 2016-02-20 |
Family
ID=42668243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2015-185A ME02296B (me) | 2009-06-25 | 2010-06-25 | Postupak za liječenje kancera dll4 antagonistom i hemoterapijskim agensom |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US8518887B2 (me) |
| EP (1) | EP2445528B1 (me) |
| JP (2) | JP6038650B2 (me) |
| KR (1) | KR101750723B1 (me) |
| CN (1) | CN102481365A (me) |
| AR (1) | AR077241A1 (me) |
| AU (1) | AU2010266004B2 (me) |
| BR (1) | BRPI1011818A2 (me) |
| CA (1) | CA2766163C (me) |
| DK (1) | DK2445528T3 (me) |
| ES (1) | ES2556804T3 (me) |
| HR (1) | HRP20160045T1 (me) |
| HU (1) | HUE026356T2 (me) |
| IL (1) | IL216952A (me) |
| ME (1) | ME02296B (me) |
| MX (1) | MX2011013424A (me) |
| MY (1) | MY173234A (me) |
| PL (1) | PL2445528T3 (me) |
| PT (1) | PT2445528E (me) |
| RS (1) | RS54477B1 (me) |
| RU (1) | RU2571220C2 (me) |
| SG (2) | SG176791A1 (me) |
| SI (1) | SI2445528T1 (me) |
| SM (1) | SMT201500315B (me) |
| TW (1) | TWI513465B (me) |
| UY (1) | UY32739A (me) |
| WO (1) | WO2010151770A1 (me) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| TWI513465B (zh) | 2009-06-25 | 2015-12-21 | Regeneron Pharma | 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法 |
| US8883145B2 (en) | 2009-10-16 | 2014-11-11 | Oncomed Pharmaceuticals, Inc. | Methods of treatment with DLL4 antagonists and an anti-hypertensive agent |
| WO2012092539A2 (en) * | 2010-12-31 | 2012-07-05 | Takeda Pharmaceutical Company Limited | Antibodies to dll4 and uses thereof |
| JP6170496B2 (ja) | 2011-09-23 | 2017-07-26 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Ｖｅｇｆ／ｄｌｌ４結合剤およびその使用 |
| GB2523211B (en) | 2012-01-27 | 2020-03-18 | Univ Jefferson | MCT protein inhibitor-related prognostic and therapeutic methods |
| US20150240240A1 (en) * | 2012-09-13 | 2015-08-27 | Thomas Jefferson University | Msf reprograms myofibroblasts toward lactate production and fuel anaerboic tumor growth |
| JP6371294B2 (ja) * | 2012-10-31 | 2018-08-08 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Ｄｌｌ４アンタゴニストによる処置の方法およびモニタリング |
| AR093445A1 (es) * | 2012-11-14 | 2015-06-10 | Regeneron Pharma | Metodos para tratar el cancer de ovario con antagonistas de dll4 |
| WO2014172627A1 (en) | 2013-04-19 | 2014-10-23 | Thomas Jefferson University | Caveolin-1 related methods for treating glioblastoma with temozolomide |
| AU2014383868A1 (en) * | 2014-02-19 | 2016-09-08 | MicroConstants China Inc, Disabled Disabled Disabled | Chemokine receptor antagonist and its combinational therapy |
| WO2016070051A2 (en) | 2014-10-31 | 2016-05-06 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| CA2998541A1 (en) * | 2015-09-16 | 2017-03-23 | Centre National De La Recherche Scientifique (Cnrs) | Gelling compositions for treating malignant tumours and/or preventing tumour recurrence |
| EP3353204B1 (en) | 2015-09-23 | 2023-10-18 | Mereo BioPharma 5, Inc. | Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer |
| CN110339350A (zh) | 2019-07-25 | 2019-10-18 | 广州中科蓝华生物科技有限公司 | 一种抗肿瘤的联合用药物组合物及其应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| EE200300179A (et) | 2000-10-13 | 2003-08-15 | Biogen, Inc. | Humaniseeritud LT-ß-R-i vastased antikehad |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| DE602004029581D1 (de) | 2003-08-13 | 2010-11-25 | Pfizer Prod Inc | Modifizierte humane igf-1r antikörper |
| US20060134121A1 (en) | 2004-10-29 | 2006-06-22 | Gavin Thurston | DII4 antagonists, assays, and therapeutic methods thereof |
| AU2006287228B2 (en) | 2005-09-01 | 2012-12-13 | Alora Biopharma, Inc. | Methods for using and identifying modulators of Delta-like 4 |
| US8329408B2 (en) * | 2005-10-31 | 2012-12-11 | Bayer Healthcare Llc | Methods for prognosis and monitoring cancer therapy |
| JP5489465B2 (ja) * | 2005-12-16 | 2014-05-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｄｌｌ４アンタゴニストによって腫瘍増殖を阻害する治療方法 |
| NZ593224A (en) * | 2006-01-11 | 2012-10-26 | Genomic Health Inc | Gene expression markers (fap) for colorectal cancer prognosis |
| KR20090016762A (ko) | 2006-06-06 | 2009-02-17 | 제넨테크, 인크. | 혈관 발달을 조정하기 위한 조성물 및 방법 |
| CA2654000A1 (en) | 2006-06-06 | 2008-05-22 | Genentech, Inc. | Anti-dll4 antibodies and methods using same |
| CA2664738C (en) * | 2006-09-29 | 2017-03-07 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
| NO347649B1 (no) * | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| US20100119526A1 (en) * | 2007-01-26 | 2010-05-13 | Bioinvent International Ab | DLL4 Signaling Inhibitors and Uses Thereof |
| EP1958632A1 (en) * | 2007-02-14 | 2008-08-20 | Dan Stoicescu | Use of condensed pyrimidine derivatives for the treatment of autoimmune and inflammatory diseases |
| EP2344536A1 (en) * | 2008-09-19 | 2011-07-20 | MedImmune, LLC | Antibodies directed to dll4 and uses thereof |
| DK2356270T3 (da) * | 2008-11-07 | 2016-12-12 | Fabrus Llc | Kombinatoriske antistofbiblioteker og anvendelser deraf |
| TWI513465B (zh) | 2009-06-25 | 2015-12-21 | Regeneron Pharma | 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法 |
-
2010
- 2010-06-24 TW TW099120547A patent/TWI513465B/zh not_active IP Right Cessation
- 2010-06-25 UY UY0001032739A patent/UY32739A/es unknown
- 2010-06-25 ME MEP-2015-185A patent/ME02296B/me unknown
- 2010-06-25 DK DK10728555.3T patent/DK2445528T3/en active
- 2010-06-25 SG SG2011091642A patent/SG176791A1/en unknown
- 2010-06-25 CA CA2766163A patent/CA2766163C/en active Active
- 2010-06-25 KR KR1020127001947A patent/KR101750723B1/ko not_active Expired - Fee Related
- 2010-06-25 MY MYPI2011005985A patent/MY173234A/en unknown
- 2010-06-25 WO PCT/US2010/039999 patent/WO2010151770A1/en not_active Ceased
- 2010-06-25 PT PT107285553T patent/PT2445528E/pt unknown
- 2010-06-25 PL PL10728555T patent/PL2445528T3/pl unknown
- 2010-06-25 ES ES10728555.3T patent/ES2556804T3/es active Active
- 2010-06-25 AR ARP100102269A patent/AR077241A1/es unknown
- 2010-06-25 HR HRP20160045TT patent/HRP20160045T1/hr unknown
- 2010-06-25 US US12/823,680 patent/US8518887B2/en active Active
- 2010-06-25 BR BRPI1011818A patent/BRPI1011818A2/pt not_active IP Right Cessation
- 2010-06-25 EP EP10728555.3A patent/EP2445528B1/en active Active
- 2010-06-25 SI SI201031078T patent/SI2445528T1/sl unknown
- 2010-06-25 RS RS20150865A patent/RS54477B1/sr unknown
- 2010-06-25 SG SG10201403568RA patent/SG10201403568RA/en unknown
- 2010-06-25 JP JP2012517770A patent/JP6038650B2/ja active Active
- 2010-06-25 MX MX2011013424A patent/MX2011013424A/es active IP Right Grant
- 2010-06-25 HU HUE10728555A patent/HUE026356T2/en unknown
- 2010-06-25 RU RU2012102415/10A patent/RU2571220C2/ru not_active IP Right Cessation
- 2010-06-25 CN CN201080037619XA patent/CN102481365A/zh active Pending
- 2010-06-25 AU AU2010266004A patent/AU2010266004B2/en active Active
-
2011
- 2011-12-13 IL IL216952A patent/IL216952A/en not_active IP Right Cessation
-
2013
- 2013-07-23 US US13/948,919 patent/US8840886B2/en active Active
-
2014
- 2014-08-12 US US14/457,968 patent/US20150064189A1/en not_active Abandoned
-
2015
- 2015-08-14 JP JP2015160020A patent/JP2016006101A/ja not_active Withdrawn
- 2015-12-15 SM SM201500315T patent/SMT201500315B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02296B (me) | Postupak za liječenje kancera dll4 antagonistom i hemoterapijskim agensom | |
| Pinto et al. | Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study) | |
| JP2008531576A5 (me) | ||
| HRP20180104T1 (hr) | Materijal i postupci za liječenje ili prevenciju bolesti povezanih s her-3 | |
| RU2011111746A (ru) | Композиции рекомбинантных антител против рецептора эпидермального фактора роста | |
| JP2019519499A5 (me) | ||
| JP2017533912A5 (me) | ||
| JP2018070648A5 (me) | ||
| RU2014138038A (ru) | Фармацевтическая композиция для лечения профилактики рака | |
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| JP6425653B2 (ja) | 抗腫瘍剤及び抗腫瘍効果増強剤 | |
| JP2008528486A5 (me) | ||
| JP2013520442A5 (me) | ||
| RU2018100424A (ru) | Комбинированная терапия для лечения злокачественной опухоли | |
| JP2019524713A5 (me) | ||
| RU2010151602A (ru) | Комбинированная терапия с помощью рм00104 и другого противоопухолевого средства | |
| RU2018122629A (ru) | Антитела против 5t4 и конъюгаты антитело-лекарственное средство | |
| JP2018512402A5 (me) | ||
| JPWO2022270524A5 (me) | ||
| Wang et al. | Treatment strategies for patients with HER2-positive gastric cancer | |
| JP2024071393A5 (me) | ||
| CN115698076A (zh) | 用于治疗肿瘤的药物 | |
| WO2017176565A1 (en) | Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor | |
| Dreanic et al. | Gastric carcinoma at the era of targeted therapies | |
| KR20200105825A (ko) | 삼중 음성 유방암의 치료를 위한 ｐｄ－１ 항체 및 아파티닙의 조합 치료의 용도 |